These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 1912366)
1. Effects of biological response modifiers on childhood ALL being in remission after chemotherapy. Kawa K; Konishi S; Tsujino G; Mabuchi S Biomed Pharmacother; 1991; 45(2-3):113-6. PubMed ID: 1912366 [TBL] [Abstract][Full Text] [Related]
2. [Direct antitumor activity of biological response modifiers (B.R.M.) proven by an in vitro sensitivity test]. Yanagawa T; Oguro M; Takagi T; Takenaga K Gan To Kagaku Ryoho; 1984 Oct; 11(10):2155-62. PubMed ID: 6486831 [TBL] [Abstract][Full Text] [Related]
3. Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Japanese experience. Shibata M; Nezu T; Fujisaki S; Andou K; Tomita R; Fukuzawa M Dig Surg; 2002; 19(4):255-60. PubMed ID: 12207066 [TBL] [Abstract][Full Text] [Related]
4. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324 [TBL] [Abstract][Full Text] [Related]
6. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study. Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291 [TBL] [Abstract][Full Text] [Related]
7. A second course of treatment for childhood acute lymphoblastic leukaemia: long-term follow-up is needed to assess results. Chessells JM; Leiper AD; Richards SM Br J Haematol; 1994 Jan; 86(1):48-54. PubMed ID: 8011547 [TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary treatment for bladder carcinoma--biological response modifiers and kampo medicines. Horii A; Kyo M; Asakawa M; Yasumoto R; Maekawa M Urol Int; 1991; 47 Suppl 1():108-12. PubMed ID: 1949364 [TBL] [Abstract][Full Text] [Related]
9. [Recent progress in biological therapies for cancer]. Saji S; Sugiyama Y; Kunieda K; Umemoto T Gan To Kagaku Ryoho; 1999 Jun; 26 Suppl 1():32-41. PubMed ID: 10410657 [TBL] [Abstract][Full Text] [Related]
10. [Differences in antitumor effect of various BRMs by intratumoral administration: induction of immunosuppressive acidic protein]. Ebina T; Murata K Gan To Kagaku Ryoho; 1993 Aug; 20(11):1453-6. PubMed ID: 8373204 [TBL] [Abstract][Full Text] [Related]
11. [Effect of concomitant use of immunomodulator (OK-432 and/or PSK) on advanced lung cancer (squamous cell carcinoma and adenocarcinoma) treated with radiation with combined chemotherapy]. Ogawa Y; Kimura S; Imajo Y; Hiratsuka J; Ichiyanagi A; Ashida C; Oshitani T; Imanaka K; Obayashi K; Takada Y Rinsho Hoshasen; 1982 Dec; 27(13):1445-8. PubMed ID: 7166858 [No Abstract] [Full Text] [Related]
12. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide. Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007 [TBL] [Abstract][Full Text] [Related]
14. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. Boulad F; Steinherz P; Reyes B; Heller G; Gillio AP; Small TN; Brochstein JA; Kernan NA; O'Reilly RJ J Clin Oncol; 1999 Jan; 17(1):197-207. PubMed ID: 10458234 [TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy of poorly immunogenic tumors with in vitro sensitized cells generated by intratumoral administration of biological response modifiers. Mukai S; Kato H; Kimura S; Asai K; Kawahito Y; Inoue M; Yamamura Y; Sano H; Sugino S; Shu S Int J Immunopharmacol; 1995 Dec; 17(12):963-71. PubMed ID: 8964655 [TBL] [Abstract][Full Text] [Related]
16. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Maehara Y; Inutsuka S; Takeuchi H; Baba H; Kusumoto H; Sugimachi K Cancer Chemother Pharmacol; 1993; 33(2):171-5. PubMed ID: 8261578 [TBL] [Abstract][Full Text] [Related]
17. [Differences of antitumor effect of various BRMs by intratumoral administration]. Ebina T; Murata K Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1429-32. PubMed ID: 1530288 [TBL] [Abstract][Full Text] [Related]
18. In vitro augmentation of cytotoxicity by N-CWS in peritoneal polymorphonuclear leukocytes (PMNs) induced by PSK, OK-432 or N-CWS. Kato H; Yamamura Y; Inoue M; Tanigawa M; Kimura S; Sugino S; Kondo M Biotherapy; 1992; 4(1):69-73. PubMed ID: 1543653 [TBL] [Abstract][Full Text] [Related]
19. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group. Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343 [TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. Barrett AJ; Horowitz MM; Pollock BH; Zhang MJ; Bortin MM; Buchanan GR; Camitta BM; Ochs J; Graham-Pole J; Rowlings PA N Engl J Med; 1994 Nov; 331(19):1253-8. PubMed ID: 7935682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]